Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.
Abstract
Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.
참고문헌 (29)
- Song IH, "Current status of liver diseases in Korea: hepatocellular carcinoma", Korean J Hepatol, 15(Suppl 6), pp.S50~S59 (2009)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Brunetto MR, "B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
- Moucari R, "Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
- Moucari R, "Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferonalpha2a", Antivir Ther, 14, pp.1183~1188 (2009)
- Hadziyannis SJ, "Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus", Hepatology, 3, pp.656~662 (1983)
- Hsu HC, "Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection", J Hepatol, 5, pp.45~50 (1987)
- Tae Hyeon Kim, "The Degrees of Hepatocyte Cytoplasmic Expression of Hepatitis B Core Antigen correlate with Histologic Activity of Liver Disease in the Young Patients with Chronic Hepatitis B Infection", Journal of Korean Medical Science, 21(2), pp.279~283 (2006), 대한의학회
- Myung Su Son, "Associations of Expressions of HBcAg and HBsAg with the Histologic Activity of Liver Disease and Viral Replication", Gut and Liver, 2(3), pp.166~173 (2008), 거트앤리버 발행위원회
- Hsu HC, "Correlation of hepatocyte HBsAg expression with virus replication and liver pathology", Hepatology, 8, pp.749~754 (1988)
- Chu CM, "Membrane staining for hepatitis B surface antigen on hepatocytes: a sensitive and specific marker of active viral replication in hepatitis B", J Clin Pathol, 48, pp.470~473 (1995)
- Uzun Y, "Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment", J Gastroenterol Hepatol, 21, pp.977~981 (2006)
- 시계동, "만성 B형간염 환자에서 hepatitis B core antigen 의 발현과 분포 위치에 따른 라마부딘의 치료반응", Clinical and Molecular Hepatology, 14(2), pp.197~205 (2008), 대한간학회
- 이정길, "Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients", Gut and Liver, 7(4), pp.462~468 (2013), 거트앤리버 발행위원회
- 조지현, "B형간염바이러스 유전자형의 국내 분포에 대한 연구", Clinical and Molecular Hepatology, 15(2), pp.140~147 (2009), 대한간학회
- Song BC, "Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection", Intervirology, 48, pp.133~137 (2005)
- Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
- Seto WK, "A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance", Hepatology, 56, pp.812~819 (2012)
- Chu CM, "The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection", J Clin Microbiol, 35, pp.102~105 (1997)
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
- Gudat F, "Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B", Lab Invest, 32, pp.1~9 (1975)
- Ray MB, "Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients", Gastroenterology, 71, pp.462~469 (1976)
- Ray MB, "Desmyter J. Distribution patterns of hepatitis B surface antigen (HBsAg) in the liver of hepatitis patients", J Clin Pathol, 29, pp.94~100 (1976)
- Huang YH, "Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads", Clin Vaccine Immunol, 17, pp.1048~1053 (2010)
- Perrillo RP, "Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B", Hepatology, 36, pp.186~194 (2002)
- Seto WK, "Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatmentexperienced chronic hepatitis B patients after three years of tenofovir treatment", J Hepatol, 59, pp.709~716 (2013)
- Zoulim F, "Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study", J Hepatol, 62, pp.56~63 (2015)
- Chan HL, "Hepatitis B surface antigen quantification: why and how to use it in 2011: a core group report", J Hepatol, 55, pp.1121~1131 (2011)
- Mondelli MU, "Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection", Clin Exp Immunol, 68, pp.242~250 (1987)